Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) of Denver announced a silicon device using its Company’s CeraShield(TM) antimicrobial technology has achieved 120 days of continuous antimicrobial efficacy. The silicon ring was tested against E. coli bacteria through daily soaking in a liquid containing at least 1,000 colony forming units (”CFUs”) of the bacteria per milliliter. CeraShield antimicrobial technology uses CSA-13 as the anti-microbial compound, a compound which showed broad efficacy against E. coli, including resistant strains such as Extended Spectrum Beta Lactamase strains (ESBLs). In the ring form, the device could be used to help prevent sexually transmitted diseases.
Another, and likely more profitable, use for the CeraShield technology is as a coating on silicone urinary catheters which frequently cause urinary tract infections from E coli. The value of this technology to hospitals increased last year when Medicare stopped reimbursing facilities for costs from urinary catheter associated infections. Estimates put the number of such infections caused by catheters at over 700,000 annually in the US. Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology.
